2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
82
Neoplasms
47
Carcinoma, Non-Small-Cell Lung
28
Colorectal Neoplasms
20
Neoplasm Metastasis
15
Multiple Myeloma
14
Thyroid Neoplasms
13
Glioma
12
Pancreatic Neoplasms
11
Hematologic Neoplasms
10
Thyroid Carcinoma, Anaplastic
9
Brain Neoplasms
8
Lung Neoplasms
7
Triple Negative Breast Neoplasms
5
Skin Neoplasms
5
Rectal Neoplasms
5
Neurofibromatosis 1
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Colonic Neoplasms
5
Breast Neoplasms
5
Astrocytoma
5
Thyroid Cancer, Papillary
4
Recurrence
4
Prostatic Neoplasms
4
Neurofibroma, Plexiform
4
Glioblastoma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Uveal Melanoma
3
Interventions
Vancomycin
4
pegfilgrastim
3
Cefepime
3
trametinib
2
liposomal amphotericin B
2
dabrafenib
2
Piperacillin, Tazobactam Drug Combination
2
Meropenem
2
Filgrastim
2
Ciprofloxacin
2
Ceftazidime
2
Caspofungin
2
ofatumumab
1
ceftobiprole medocaril
1
Teicoplanin
1
Tazobactam
1
Surveys and Questionnaires
1
Ritonavir
1
Quality of Life
1
Povidone-Iodine
1
Piperacillin
1
Moxifloxacin
1
Metformin
1
Mannose-Binding Lectin
1
Levofloxacin
1
Lenalidomide
1
Itraconazole
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Granulocyte Colony-Stimulating Factor
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Fever
×
trametinib
×
Clear all
NCT01972347
2025-12-16
Neo Combi
Melanoma Institute Australia
Phase 2
Active not recruiting
35 enrolled
NCT03551626
2025-04-29
COMBI-APlus
Novartis
Phase 3
Completed
552 enrolled
12 charts